Fsd Pharma Stock News

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that it has formed a regulatory advisory board and has appointed Joga Gobburu and Mary Melnyk as members. The Toronto-based company said that the regul

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a po

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of asse

VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing

(PR-inside.com) VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company''s latest press release through exclusive insights and interviews with company executives. Lumiera (TSXV:NHP) ends fiscal year on a high note with strong sales in November Lumiera Health (NHP) recorded a 30 per cent increase in Q4 2021 versus Q4 2020. The company saw a 59 ..

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects… The post FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models appeared first on The Market Herald .

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc shared pre-clinical data, demonstrating the potentially disease-modifying effects of Lucid-MS —the company's lead drug candidate for the potential treatment of

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (FSD Pharma or the Company), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board. Dr. Fish, an accomplished researcher in the areas of immunology and inflammatory disorders, and member of the Government of Canadas Expert Scientific Panel to the Chief Scientific Ad

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc said it has expanded its team by appointing Dr Eleanor N. Fish to its Research and Clinical Advisory Board.

Focused on lead anti-inflammatory drug FSD-201 Launched Phase 2 study of drug known as micro PEA in December 2020 Developing drugs to treat gastrointestinal diseases in dogs and cats What FSD Pharm

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc said it has expanded its team by appointing Eleanor N. Fish to its Research and Clinical Advisory Board.

FSD Pharma Inc said it has entered into an agreement with Covar Pharmaceuticals Inc, a contract development and manufacturing services organization, to start work on providing research quantities of

Focused on lead anti-inflammatory drug FSD-201 Launched Phase 2 study of drug known as micro PEA in December 2020 Developing drugs to treat gastrointestinal diseases in dogs and cats What FSD Pharm

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a p

FSD Pharma Inc said it has completed its previously-announced acquisition of Canadian psychedelic pharmaceutical company Lucid Psycheceuticals Inc for about C$11.3 million in FSD Pharma stock. FSD P